Accessibility Statement Skip Navigation
  • Resources
  • Data Privacy
  • Contact Us
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • All Multimedia

        • All Multimedia
        • All Photos
        • All Videos
    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Accessories
        • Computer Hardware
        • Computer Networks
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High-Tech Security
        • Internet Technology
        • Nanotechnology
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art, Culture & Design
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Projections or Forecasts
        • Financing Agreements
        • Insurance
        • Joint Ventures
        • Mutual Funds
        • Offerings
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing/marketing agreements
        • New Products & Services
        • Obituary
        • Outsourcing Businesses
        • Overseas Real Estate (Non-US)
        • Personnel Announcements
        • Residential Real Estate
        • Small-Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Accessories
        • Computer Electronics
        • Computer Hardware
        • Computer Networks
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Design Automation
        • Financial Technology
        • Mobile Devices/Apps
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Natural Gas Utilities
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Computer Accessories
        • Computer Networks
        • Mobile Devices/Apps
        • Telecommunications
        • Telecommunications Carriers & Services
        • Telecommunications Equipment
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wine & Spirits
        • Beverages
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art, Culture & Design
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infectious Disease Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental Products & Services
        • European Government
        • Natural Disasters
        • Not-for-Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Children-related news
        • Disabled Persons
        • Diversity, Equity & Inclusion
        • Hispanic-oriented news
        • LGBTQ+
        • Religion
        • Senior Citizens
        • Veterans
        • Women-Related news
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Request a Demo
    • Partnerships
    • Media Inquiries
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring Home
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us


    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • News Releases
      • Send a Release
      • Data Privacy
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • News Releases
      • Send a Release
      • Data Privacy
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • News Releases
      • Send a Release
      • Data Privacy
      • General Inquiries
      • Request a Demo
      • Partnerships
      • Media Inquiries
      • Editorial Bureaus
      • News Releases
      • Send a Release
      • Data Privacy
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • All Multimedia
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Prenetics Announces First Quarter 2024 Financial Results


      News provided by

      Prenetics

      18 Jun, 2024, 20:30 CST

      Share this article

      Share this article


      First Quarter Revenue Increased 30.2% and Gross Profit Increased 159.8% from Prior Year Quarter

      Confirms Strategic Pivot Targeting the U.S. Consumer Healthcare Market 

      Reaffirms 2024 Revenue Range of US$33 million to US$36 million

      LOS ANGELES, June 18, 2024 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the first quarter ended March 31, 2024, along with recent business updates.

      First Quarter 2024 Financial Highlights

      • Revenue from continuing operations of US$6.4 million in the first quarter 2024, an increase of 30.2% as compared to the first quarter 2023.
      • Gross profit from continuing operations of US$3.8 million in the first quarter 2024, an increase of 159.8% as compared to the first quarter 2023.
      • Adjusted EBITDA from continuing operations of US$(4.1) million in the first quarter 2024, an improvement of 55.9% as compared to the first quarter 2023.
      • Cash and other short-term assets[1] of US$86.6 million as of March 31, 2024. Additionally, Insighta[2], our 50/50 joint venture in early cancer detection with Professor Dennis Lo, had a cash balance of US$79.8 million in its balance sheet as of March 31, 2024.

      Danny Yeung, Chief Executive Officer and Co-Founder of Prenetics remarked: "The first quarter of 2024 marked a good start for our company, showcasing solid growth in revenue and gross profit. These results demonstrate firm governance of our financial position with no debt supported by a resilient and talented team.

      As we enter the second half of 2024, we are making significant strides in our strategic realignment with a keen focus on the consumer healthcare market in the USA. Our purpose remains dedicated to our science first approach in our pivot to consumer healthcare to broaden accessibility to science based health and wellness. To support this growth, we have established dual headquarters with a presence in the US which will position us to seize new opportunities both domestically and globally. We look forward to sharing more details on the new direction of Prenetics in the near future," concluded Mr. Yeung.

      Recent Business Updates

      • Continued improvement on financial performance, achieving 30.2% increase in revenue from continuing operations, a 55.9% reduction in adjusted EBITDA loss, and ended the quarter with strong financial position of cash and short-term assets position of US$86.6 million as of March 31, 2024.
      • Initiate a strategic realignment with an accelerated focus on the consumer healthcare sector, presenting vast global opportunities, beginning with the USA.
      • Insighta, the Company's early cancer detection venture continues to show significant progress as initial pre-clinical data on Prostate cancer shows very promising results.
      • Insighta has received all approvals necessary to move forward with a 1,500 person clinical trial with patient recruitment to begin in July 2024.

      [1] Represents current assets, including cash and cash equivalents and short-term deposits totaling US$54.5 million, financial assets at fair value through profit or loss of US$11.0 million, and trade receivables of US$4.1 million, amongst other accounting line items under current assets.

      [2] As of March 31, 2024, we owned 50% shareholding in Insighta, which was accounted for under equity-accounted investee. Equity-accounted investees, totaling US$98.2 million as of March 31, 2024, were classified as non-current assets on our balance sheet.

      About Prenetics

      Prenetics (NASDAQ:PRE), a leading genomics-driven health sciences company, is revolutionizing prevention, early detection, and treatment. Our prevention arm, CircleDNA, uses whole exome sequencing to offer the world's most comprehensive consumer DNA test. Insighta, our $200 million joint venture with renowned scientist Prof. Dennis Lo, underscores our unwavering commitment to saving lives through pioneering multi-cancer early detection technologies. Lastly, ACT Genomics, our treatment unit, is the first Asia-based company to achieve FDA clearance for comprehensive genomic profiling of solid tumors via ACTOnco. Each of Prenetics' units synergistically enhances our global impact on health, truly embodying our commitment to 'enhancing life through science'. To learn more about Prenetics, please visit www.prenetics.com. 

      Forward-Looking Statements 

      This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: the Company's ability to further develop and grow its business, including new products and services; its ability to execute on its new business strategy in genomics, precision oncology, and specifically, early detection for cancer; the results of case control studies and/or clinical trials; and its ability to identify and execute on M&A opportunities, especially in precision oncology. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the "Risk Factors" section of the Company's most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

      Basis of Presentation

      Unaudited Non-IFRS Financial Measures has been provided in the financial statements tables included at the end of this press release. An explanation of these measures is also included below under the heading "Unaudited Non-IFRS Financial Measures".

      Unaudited Non-IFRS Financial Measures

      To supplement Prenetics' consolidated financial statements prepared in accordance with International Financial Reporting Standards ("IFRS"), the Company is providing non-IFRS measures, adjusted EBITDA from continuing operations, adjusted gross profit from continuing operations and adjusted loss attributable to equity shareholders of Prenetics. These non-IFRS financial measures are not based on any standardized methodology prescribed by IFRS and are not necessarily comparable to similarly-titled measures presented by other companies. Management believes these non-IFRS financial measures are useful to investors in evaluating the Company's ongoing operating results and trends.

      Management is excluding from some or all of its non-IFRS results (1) Employee equity-settled share-based payment expenses, (2) depreciation and amortization, (3) finance income and exchange gain or loss, net, and (4) certain items that may not be indicative of our business, results of operations, or outlook, including but not limited to non-cash and/ or non-recurring items. These non-IFRS financial measures are limited in value because they exclude certain items that may have a material impact on the reported financial results. Management accounts for this limitation by analyzing results on an IFRS basis as well as a non-IFRS basis and also by providing IFRS measures in the Company's public disclosures.

      In addition, other companies, including companies in the same industry, may not use the same non-IFRS measures or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-IFRS measures as comparative measures. Because of these limitations, the Company's non-IFRS financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with IFRS. Investors are encouraged to review the non-IFRS reconciliations provided in the tables captioned "Reconciliation of loss from operations from continuing operations under IFRS and adjusted EBITDA from continuing operations (Non-IFRS)", "Reconciliation of gross profit from continuing operations under IFRS and adjusted gross profit from continuing operations (Non-IFRS)" and "Reconciliation of loss attributable to equity shareholders of Prenetics under IFRS and adjusted loss attributable to equity shareholders of Prenetics (Non-IFRS)" set forth at the end of this document.

      PRENETICS GLOBAL LIMITED

      Unaudited consolidated statements of financial position

      (Expressed in United States dollars unless otherwise indicated)



      March 31,


      December 31,


      2024


      2023

      Assets




      Property, plant and equipment

      $             4,585,957


      $             5,777,794

      Intangible assets

      13,169,672


      13,424,648

      Goodwill

      29,170,123


      29,170,123

      Interests in equity-accounted investees

      98,244,733


      98,464,875

      Financial assets at fair value through profit or loss

      9,371,064


      9,371,064

      Deferred tax assets

      27,630


      27,680

      Deferred expenses

      1,483,348


      3,530,756

      Other non-current assets

      948,811


      743,173

      Non-current assets

      157,001,338


      160,510,113

      Deferred expenses

      8,272,025


      8,312,890

      Inventories

      2,815,607


      3,126,776

      Trade receivables

      4,106,052


      4,058,007

      Deposits, prepayments and other receivables

      5,708,610


      5,284,848

      Amount due from a related company

      2,556


      5,123

      Amount due from an equity-accounted investee

      126,177


      132,114

      Financial assets at fair value through profit or loss

      11,034,200


      11,034,200

      Short-term deposits

      —


      16,000,000

      Cash and cash equivalents

      54,518,588


      45,706,448

      Current assets

      86,583,815


      93,660,406

      Total assets

      $         243,585,153


      $         254,170,519

      Liabilities




      Deferred tax liabilities

      $             2,327,331


      $             2,614,823

      Warrant liabilities

      143,264


      223,850

      Lease liabilities

      669,373


      867,215

      Other non-current liabilities

      464,215


      823,345

      Non-current liabilities

      3,604,183


      4,529,233

      Trade payables

      1,637,568


      1,671,019

      Accrued expenses and other current liabilities

      7,100,324


      8,174,815

      Contract liabilities

      5,542,678


      6,111,017

      Lease liabilities

      1,079,449


      1,502,173

      Liabilities for puttable financial instrument[3]

      14,472,666


      14,622,529

      Tax payable

      7,385,897


      7,402,461

      Current liabilities

      37,218,582


      39,484,014

      Total liabilities

      40,822,765


      44,013,247

      Equity




      Share capital[4]

      18,326


      18,308

      Reserves

      199,425,243


      206,339,490

      Total equity attributable to equity shareholders of the Company

      199,443,569


      206,357,798

      Non-controlling interests

      3,318,819


      3,799,474

      Total equity

      202,762,388


      210,157,272

      Total equity and liabilities

      $         243,585,153


      $         254,170,519

      PRENETICS GLOBAL LIMITED

      Unaudited consolidated statements of profit or loss and other comprehensive income

      (Expressed in United States dollars unless otherwise indicated)



      Three Months Ended


      March 31,


      December 31,


      March 31,


      2024


      2023


      2023






      (Restated)

      Continuing operations






      Revenue

      $             6,413,397


      $             5,428,460


      $             4,924,035

      Direct costs

      (2,630,751)


      (2,758,288)


      (3,467,939)

      Gross profit

      3,782,646


      2,670,172


      1,456,096

      Other income and other net gain

      747,891


      715,562


      1,077,091

      Selling and distribution expenses[5]

      (1,898,473)


      (1,908,415)


      (2,501,274)

      Research and development expenses[5]

      (2,731,050)


      (2,586,477)


      (3,233,538)

      Impairment loss of goodwill

      —


      (3,900,268)


      —

      Administrative and other operating expenses[5]

      (9,059,929)


      (10,362,374)


      (11,689,809)

      Loss from operations

      (9,158,915)


      (15,371,800)


      (14,891,434)

      Fair value loss on financial assets at fair value through
          profit or loss

      —


      (3,190,379)


      —

      Fair value gain on warrant liabilities

      80,586


      671,550


      1,260,276

      Share of loss of equity-accounted investees

      (216,245)


      (688,183)


      (112,751)

      Other finance (costs)/income

      (16,339)


      1,073


      (43,844)

      Loss before taxation

      (9,310,913)


      (18,577,739)


      (13,787,753)

      Income tax credit/(expense)

      285,938


      (10,678)


      80,655

      Loss from continuing operations

      (9,024,975)


      (18,588,417)


      (13,707,098)

      Discontinued operation






      (Loss)/profit from discontinued operation, net of tax[6]

      (26,615)


      (1,026,983)


      2,733,358

      Loss for the period

      (9,051,590)


      (19,615,400)


      (10,973,740)

      Other comprehensive income for the period






      Item that may be reclassified subsequently to profit or loss:






      Exchange difference on translation of foreign operations

      (430,444)


      1,118,149


      (636,502)

      Total comprehensive income for the period

      $           (9,482,034)


      $         (18,497,251)


      $         (11,610,242)

      Loss attributable to:






      Equity shareholders of Prenetics

      $           (8,568,095)


      $         (19,047,124)


      $         (10,398,430)

      Non-controlling interests

      (483,495)


      (568,276)


      (575,310)


      $           (9,051,590)


      $         (19,615,400)


      $         (10,973,740)

      Total comprehensive income attributable to:






      Equity shareholders of Prenetics

      $           (9,001,379)


      $         (18,677,610)


      $         (10,495,918)

      Non-controlling interests

      (480,655)


      180,359


      (1,114,324)


      $           (9,482,034)


      $         (18,497,251)


      $         (11,610,242)

      Loss per share:






      Basic

      $                    (0.70)


      $                    (1.57)


      (0.99)

      Diluted

      (0.70)


      (1.57)


      (0.99)

      Loss per share - Continuing operations:






      Basic

      (0.70)


      (1.49)


      (1.25)

      Diluted

      (0.70)


      (1.49)


      (1.25)

      Weighted average number of common shares:






      Basic

      12,215,904


      12,114,922


      10,522,621

      Diluted

      12,215,904


      12,114,922


      10,522,621

      PRENETICS GLOBAL LIMITED

      Unaudited Non-IFRS Financial Measures

      (Expressed in United States dollars unless otherwise indicated)


      Reconciliation of loss from operations from continuing operations under IFRS and adjusted EBITDA from
      continuing operations (Non-IFRS)



      Three Months Ended


      March 31,


      December 31,


      March 31,


      2024


      2023


      2023






      (Restated)

      Loss from operations from continuing operations
          under IFRS

      $           (9,158,915)


      $         (15,371,800)


      $         (14,891,434)

      Employee equity-settled share-based payment expenses

      1,937,268


      2,055,858


      2,940,984

      Depreciation and amortization

      1,719,555


      1,564,816


      1,796,990

      Other strategic financing, transactional expense and non-
          recurring expenses

      2,096,563


      6,263,188


      1,847,131

      Finance income, exchange gain or loss, net

      (700,589)


      (673,740)


      (1,000,131)

      Adjusted EBITDA from continuing operations (Non-
          IFRS)

      $           (4,106,118)


      $           (6,161,678)


      $           (9,306,460)


      Reconciliation of gross profit from continuing operations under IFRS and adjusted gross profit from continuing
      operations (Non-IFRS)



      Three Months Ended


      March 31,


      December 31,


      March 31,


      2024


      2023


      2023






      (Restated)

      Gross profit from continuing operations under IFRS

      $             3,782,646


      $             2,670,172


      $             1,456,096

      Employee equity-settled share-based payment expenses

      581


      11,522


      —

      Depreciation and amortization

      279,561


      309,812


      384,326

      Adjusted gross profit from continuing operations (Non-
          IFRS)

      $             4,062,788


      $             2,991,506


      $             1,840,422


      Reconciliation of loss attributable to equity shareholders of Prenetics under IFRS and adjusted loss attributable
      to equity shareholders of Prenetics (Non-IFRS)



      Three Months Ended


      March 31,


      December 31,


      March 31,


      2024


      2023


      2023






      (Restated)

      Loss attributable to equity shareholders of Prenetics
          under IFRS

      $           (8,568,095)


      $         (19,047,124)


      $         (10,398,430)

      Employee equity-settled share-based payment expenses

      1,937,268


      2,055,858


      3,124,189

      Other strategic financing, transactional expense and non-
          recurring expenses

      2,096,563


      8,248,151


      3,161,638

      Fair value gain on warrant liabilities

      (80,586)


      (671,550)


      (1,260,276)

      Fair value loss on financial assets at fair value through
          profit or loss

      —


      3,190,379


      —

      Adjusted loss attributable to equity shareholders of
          Prenetics (Non-IFRS)

      $           (4,614,850)


      $           (6,224,286)


      $           (5,372,879)

      [3] In connection with the acquisition of ACT Genomics, the remaining shareholders of ACT Genomics - representing 25.61% of
      the fully diluted shareholding of ACT Genomics that Prenetics does not own - were granted put options which allow these
      remaining shareholders to put their remaining shares to Prenetics under certain conditions. The liabilities arising from such put
      option are recorded as liabilities for puttable financial instrument, and are valued at the present value of the exercise price of the
      put option.


      [4] Represents number of authorized and issued shares as follows:



      March 31,


      December 31,


      2024


      2023

      Number of authorized shares of $0.0015 each

      33,333,333


      33,333,333

      Number of issued shares

      12,217,226


      12,205,200

      [5] Includes equity-settled share-based payment expenses from continuing operations as follows:



      Three Months Ended


      March 31,


      December 31,


      March 31,


      2024


      2023


      2023






      (Restated)

      Direct costs

      $                       581


      $                  11,522


      $                         —

      Selling and distribution expenses

      1,053


      (632)


      45,255

      Research and development expenses

      758,394


      675,928


      486,507

      Administrative and other operating expenses

      1,155,752


      1,339,419


      2,391,044

      Total equity-settled share-based payment expenses

      $             1,915,780


      $             2,026,237


      $             2,922,806



      [6] We ceased our COVID-19 testing business entirely in 2023 Q2, and other DNA testing operations in the EMEA regions in 2023
      Q4. As a result, COVID-19 testing business and the operations in the EMEA regions are reported as a discontinued operation
      under IFRS 5 Non-current Assets Held for Sale and Discontinued Operations. In accordance with IFRS 5, the results of the
      discontinued operation have been presented separately from the continuing operations in the consolidated statements of profit or
      loss and other comprehensive income. The comparative information in the consolidated statements of profit or loss and other
      comprehensive income has also been re-presented to show the results of discontinued operation separately.

      SOURCE Prenetics

      Modal title

      Contact PR Newswire

      • General Inquiries
      • Request a Demo
      • Partnerships
      • Media Inquiries

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Become a Publishing Partner
      • Careers
      • Accessibility Statement
      • APAC – Simplified Chinese
      • APAC
      • APAC - Traditional Chinese
      • Arabic
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • United States
      • Vietnam

      My Services

      • All New Releases
      • Platform

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Platform
      [email protected]
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      • Accessibility
      Copyright © 2026 Cision US Inc.